Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

VTE (Venous Thromboembolism): full-pipeline trial registry

2 of 2 indexed VTE (Venous Thromboembolism) trials are currently recruiting.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

VTE (Venous Thromboembolism): 2 US clinical trials tracked, 2 recruiting.

VTE (Venous Thromboembolism) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Vermont, running 1 of these trials.

Enrollment posture brief

Registry condition vte-venous-thromboembolism

OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

VTE (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near VTE (Venous Thromboembolism)

VTE (Venous Thromboembolism) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for VTE (Venous Thromboembolism) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. VTE (Venous Thromboembolism) is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on VTE (Venous Thromboembolism) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rivaroxaban 20 MG Oral Tablet Drug
1 trials
Rivaroxaban 10 MG Oral Tablet Drug
1 trials
No anticoagulation Drug
1 trials
Apixaban 5 mg once daily Drug
1 trials
Apixaban 2.5 mg twice daily Drug
1 trials

US sites by state

Facility locations filed on VTE (Venous Thromboembolism) trials. A trial with sites in several states counts in each.

Vermont 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this VTE (Venous Thromboembolism) page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 VTE (Venous Thromboembolism) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Vermont sponsors the most VTE (Venous Thromboembolism) trials on record, review their full trial history before evaluating a specific study. See University of Vermont's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This VTE (Venous Thromboembolism) condition card totals 2 registered trials; most-linked intervention Rivaroxaban 20 MG Oral Tablet; top US site state Vermont. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.